Treatment of metronidazole-resistant Trichomonas vaginalis
Linda M. Goldman A D , Jacqueline A. Upcroft B , Kimberly Workowski C and Andrea Rapkin AA The David Geffen School of Medicine, UCLA, 200 Medical Plaza Suite #430, Los Angeles, CA 90095, USA.
B Queensland Institute of Medical Research, The Bancroft Centre, 300 Herston Road, Brisbane, Qld 4006, Australia.
C Emory University Division of Infectious Diseases, 550 Peachtree Street, Suite 7000, Atlanta, GA 30308, USA.
D Corresponding author. Email: lgoldman@mednet.ucla.edu
Sexual Health 6(4) 345-347 https://doi.org/10.1071/SH09064
Submitted: 17 June 2009 Accepted: 10 July 2009 Published: 13 November 2009
Abstract
A 58-year-old Caucasian woman presented with a 14-month history of persistent trichomoniasis not responsive to numerous courses of metronidazole and tinidazole. Vaginal secretion samples were obtained for sensitivity testing and treatment recommendations. In vitro susceptibility testing revealed the patient’s Trichomonas vaginalis isolate was highly resistant to both metronidazole and tinidazole. She was treated with topical furazolidone and experienced a complete symptomatic cure and culture remained negative 35 days post furazolidone treatment.
Additional keywords: compounding pharmacy, nonoxynol-9, tinidazole, topical furazolidone.
Acknowledgements
We would like to thank and acknowledge Patricia Johnson, Felix Bastida and Maria G. Delgadillo-Correa (UCLA) for their help and expertise in Trichomonas cultivation and Evan Secor, PhD (CDC) for drug sensitivity testing.
[1] Cotch MF, Pastorek JG, Nugent RP, Hillier SL, Gibbs RS, Martin DH, et al. Trichomonas vaginalis associated with low birth weight and preterm delivery. The Vaginal Infections and Prematurity Study Group. Sex Transm Dis 1997; 24 353–60.
| Crossref | GoogleScholarGoogle Scholar | CAS | PubMed |
[2] Dunne R, Dunn L, Upcroft P, O’Donoghue P, Upcroft J. Drug resistance in the sexually transmitted protozoan Trichomonas vaginalis. Cell Res 2003; 13 239–49.
| Crossref | GoogleScholarGoogle Scholar | CAS | PubMed |
[3] Upcroft P, Upcroft JA. Drug targets and mechanisms of resistance in the anaerobic protozoa. Clin Microbiol Rev 2001; 14 150–64.
| Crossref | GoogleScholarGoogle Scholar | CAS | PubMed |
[4] Centers for Disease Control and Prevention Sexually transmitted diseases treatment guidelines 2002. MMWR Recomm Rep 2002; 51 No. RR-6.
[5] Sobel JD, Nagappan V, Nyierjesy P. Metronidazole-resistant vaginal trichomoniasis an emerging problem. N Engl J Med 1999; 341 292–3.
| Crossref | GoogleScholarGoogle Scholar | CAS | PubMed |
[6] Schwebke JR, Barrientes FJ. Prevalence of Trichomonas vaginalis isolates with resistance to metronidazole and tinidazole. Antimicrob Agents Chemother 2006; 50 4209–10.
| Crossref | GoogleScholarGoogle Scholar | CAS | PubMed |
[7] Schmid G, Narcisi E, Mosure D, Secor WE, Higgins J, Moreno H. Prevalence of metronidazole resistant Trichomonas vaginalis in a gynecology clinic. J Reprod Med 2001; 46 545–9.
| CAS | PubMed |
[8] Narcisi EM, Secor WE. In vitro effect of tinidazole and furazolidone on metronidazole-resistant Trichomonas vaginalis. Antimicrob Agents Chemother 1996; 40 1121–5.
| CAS | PubMed |
[9] Upcroft J, Upcroft P. Drug susceptibility testing of the anaerobic protozoa. Antimicrob Agents Chemother 2001; 45 1810–4.
| Crossref | GoogleScholarGoogle Scholar | CAS | PubMed |
[10] Voolmann T, Boreham P. Metronidazole-resistant Trichomonas vaginalis in Brisbane. Med J Aust 1993; 159 490.
| CAS | PubMed |
[11] Sobel JD, Nyirjesy P, Brown W. Tinidazole therapy for metronidazole-resistant vaginal trichomoniasis. Clin Infect Dis 2001; 33 1341–6.
| Crossref | GoogleScholarGoogle Scholar | CAS | PubMed |
[12] Raether W, Hanel H. Nitroheterocyclic drugs with broad spectrum activity. Parasitol Res 2003; 90 S19–39.
| PubMed |
